XLV - Karyopharm Stock Down From Peak Despite Commercial Progress And Strong Data Provides Investor Opportunity
Karyopharm is a top idea for several reasons, the lead one being the company's first approved drug Xpovio for multiple myeloma MM, a type of blood cancer. Approved in the U.S. in July 2019, this drug has significant potential in MM and other indications, and with multi-billion-dollar annual sales potential, KPTI is trading at a mere fraction of where the stock could end up going. A healthy drug pipeline with compounds addressing other blood cancers as well as solid tumors, and a wildcard potential COVID-19 treatment indication for Xpovio, we believe there are multiple chances